Related Experiment Video
Updated: Aug 11, 2026
03:25
Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease
Published on: December 27, 2024
[Smectite in AIDS-associated chronic idiopathic diarrhea]
A Mastroianni1, C Cancellieri, O Coronado
1Divisione di Malattie Infettive, Ospedale G. B. Morgagni, Forlì.
Minerva Gastroenterologica E Dietologica
|February 24, 2006
Summary
Smectite effectively reduced chronic diarrhea symptoms in AIDS patients. This treatment demonstrated significant efficacy and good tolerability, offering a valuable option for managing this condition.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Clinical Pharmacology
Context:
- Chronic idiopathic diarrhea is a common complication in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Managing diarrhea in AIDS patients is crucial for improving quality of life and nutritional status.
- Existing treatments may have limitations or side effects, necessitating exploration of alternative therapies.
Purpose:
- To evaluate the efficacy and tolerability of Smectite as a treatment for chronic idiopathic diarrhea in patients with AIDS.
- To assess the impact of Smectite on diarrhea duration, stool frequency, and stool liquidity.
Summary:
- A prospective clinical study involved 22 patients diagnosed with AIDS-associated chronic idiopathic diarrhea.
- Patients received Smectite at a dosage of 3 g orally, three times daily, for 10-21 days.
- Significant reductions in diarrhea duration, stool frequency, and liquid stool volume were observed by the third and fourth treatment days.
Impact:
- Smectite demonstrates significant efficacy in alleviating symptoms of chronic diarrhea in AIDS patients.
- The treatment is well-tolerated, with no major adverse effects or drug interactions reported.
- Smectite presents a promising adjuvant therapy option for managing AIDS-associated chronic idiopathic diarrhea.
Related Concept Videos
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:12Giardiasis
Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.